Synthesis and Prophylactic Use of Humanized Neutralizing Monoclonal SLT-I and SLT-II Antibodies Against Hemolytic Uremic Syndrome (HUS) in Children.

The invention relates in one aspect to a therapeutic method to treat hemolytic uremic syndrome by administering to an individual a therapeutically effective amount of monoclonal antibody which binds specifically to either Shiga toxin, Shiga like toxin I or Shiga like toxin II. The hemolytic uremic syndrome is typically caused by an Enterohemorrhagic Escherichia coli. Shiga toxin which is identical to SLT-I is produced by Shigella sp.

Licensing Contact

Robert Benson
bob@southshakerassociates.com